Everything You Need to Know (FLM) Haematology block
Measuring Angiogenesis in Hematologic Diseases Maher Albitar, MD Quest Diagnostics, Nichols Institute San Juan Capistrano, CA 92690 (949)728-4784 [email protected].
Progress Against Leukemia. 1970–1979 Progress Against Leukemia 1970–1979 1974: FDA approves doxorubicin.
Molecular Pathogenesis of Leukemia PML/RAR MLL translocations PLZF/RAR etc. AML1/ETO CBF /SMMHC TEL/AML1 Other transloc. BCR-ABL Flt3 ITD or mutation.
MDS: Classification and Advances in Therapy BTG2013 S. Varma PGIMER, Chandigarh India.
EHA highlights News in MDS JULY31, TYR,LEBANON MARCEL MASSOUD, M.D.
Myelodysplastic, Myeloproliferative, and Histiocytic Disorders Kenneth McClain M.D. Ph.D. Texas Children’s Cancer Center Houston, TX.
Gba and Zor Joint Communities Forest Management Body Inc. (JCFMB) Mining Concessions and Community Forestry Saye Thompson Chairman JCFMB.
Cancers of the Bone Marrow: A Clinical Perspective Mary Ward, RN, BS, CTR.
Computational Identification of Tumor heterogeneity 2015-03-25 Sangwoo Kim.
Leukemias. Etiology of Leukemias General outlines Acute leukemias Single cell mutation with “freezing” farther cell’s differentiation and maturation in.
What is AML? What is a program? What is AML? An AML can: –Automate frequently performed actions –Provide a quick and consistent way to set environments.